- Report
- June 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,163GBP
- Report
- June 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,163GBP
- Report
- June 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,163GBP
- Report
- June 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,163GBP
- Report
- June 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,163GBP
- Report
- June 2023
- 132 Pages
Global
From €919EUR$950USD£775GBP
- Report
- March 2024
- 132 Pages
Global
From €919EUR$950USD£775GBP
- Report
- November 2023
- 211 Pages
China
From €3868EUR$4,000USD£3,264GBP
- Book
- December 2018
- 245 Pages
- Report
- August 2023
- 270 Pages
Global
From €2369EUR$2,450USD£1,999GBP
- Report
- April 2023
- 447 Pages
Global
From €3568EUR$3,690USD£3,011GBP
- Report
- October 2021
- 234 Pages
Global
From €3589EUR$3,712USD£3,029GBP
- Report
- April 2024
- 160 Pages
Global
From €5801EUR$5,999USD£4,896GBP
The Anti-Obesity Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs designed to reduce or prevent obesity. These drugs are typically prescribed to individuals who are overweight or obese and are at risk of developing health complications due to their weight. Commonly prescribed anti-obesity drugs include orlistat, lorcaserin, and phentermine. These drugs work by suppressing appetite, increasing metabolism, or blocking the absorption of fat.
The Anti-Obesity Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Novo Nordisk, Sanofi, Pfizer, and Merck. These companies are constantly developing new drugs and treatments to meet the needs of their customers. Show Less Read more